Literature DB >> 26019274

Photosensitizer and Light Pave the Way for Cytosolic Targeting and Generation of Cytosolic CD8 T Cells Using PLGA Vaccine Particles.

Cristina Bruno1, Ying Waeckerle-Men2, Monika Håkerud3, Thomas M Kündig2, Bruno Gander4, Pål Johansen5.   

Abstract

The generation of CTLs is crucial in the immunological fight against cancer and many infectious diseases. To achieve this, vaccine Ags need to be targeted to the cytosol of dendritic cells, which can activate CD8 T cells via MHC class I (MHCI). Therefore, such targeting has become one of the major objectives of vaccine research. In this study, we aimed to bypass the unwanted and default MHC class II Ag presentation and trigger MHCI presentation by using a photosensitizer that, upon light activation, would facilitate cytosolic targeting of codelivered Ag. Poly(lactide-co-glycolide) microparticles ∼1 μm size were loaded with OVA and the photosensitizer tetraphenyl chlorine disulphonate (TPCS2a) and administered intradermally in mice, which were illuminated 1 d later for activation of the photosensitizer. Immunization in the presence of TPCS2a significantly increased activation of CD8 T cells compared with immunization without TPCS2a and as measured by CD8 T cell proliferation, production of proinflammatory IFN-γ, TNF-α, and IL-2, and prevention of tumor growth. Cytotoxicity was demonstrated by granzyme B production in vitro and by in vivo killing of CFSE-labeled targets. CD4-dependent Ab responses were abrogated in mice immunized with TPCS2a-containing particles, suggesting that photosensitization facilitated a shift from default MHC class II toward MHCI Ag presentation. Hence, vaccine particles with Ag and photosensitizers proved an effective vehicle or adjuvant for stimulation of CTLs, and they may find potential application in therapeutic cancer vaccination and in prophylactic and therapeutic vaccination against intracellular infections.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26019274     DOI: 10.4049/jimmunol.1500431

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.

Authors:  Markus Haug; Gaute Brede; Monika Håkerud; Anne Grete Nedberg; Odrun A Gederaas; Trude H Flo; Victoria T Edwards; Pål K Selbo; Anders Høgset; Øyvind Halaas
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

2.  Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.

Authors:  Eleni Maria Varypataki; Fabio Hasler; Ying Waeckerle-Men; Sarah Vogel-Kindgen; Anders Høgset; Thomas M Kündig; Bruno Gander; Cornelia Halin; Pål Johansen
Journal:  Front Immunol       Date:  2019-07-05       Impact factor: 7.561

Review 3.  The Role of Nanovaccine in Cross-Presentation of Antigen-Presenting Cells for the Activation of CD8+ T Cell Responses.

Authors:  Cheol Gyun Kim; Yoon-Chul Kye; Cheol-Heui Yun
Journal:  Pharmaceutics       Date:  2019-11-15       Impact factor: 6.321

4.  Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers.

Authors:  Tone Otterhaug; Sylvia Janetzki; Marij J P Welters; Monika Håkerud; Anne Grete Nedberg; Victoria Tudor Edwards; Sanne Boekestijn; Nikki M Loof; Pål Kristian Selbo; Hans Olivecrona; Sjoerd H van der Burg; Anders Høgset
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

5.  Photochemically-Mediated Inflammation and Cross-Presentation of Mycobacterium bovis BCG Proteins Stimulates Strong CD4 and CD8 T-Cell Responses in Mice.

Authors:  Ying Waeckerle-Men; Zuzanna K Kotkowska; Géraldine Bono; Agathe Duda; Isabel Kolm; Eleni M Varypataki; Beat Amstutz; Michael Meuli; Anders Høgset; Thomas M Kündig; Cornelia Halin; Peter Sander; Pål Johansen
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.